

# Prism Medico & Pharmacy Limited

CIN: L51109MH2002PLC206595

23/91, White Bungalow, Yashwant Nagar,  
Near Filmistan Studio & Patkar College,  
Opposite BMC School, Goregaon West,  
Mumbai-400062  
Telephone no – 022 28733312  
Website: [www.prismmedico.com](http://www.prismmedico.com)  
Email Id – investorgrivancewmcl@gmail.com

Date: 04/12/2017

To,

Department of Corporate Services,  
**BSE LIMITED**  
P. J. Towers, Dalal Street,  
Mumbai – 400 001.

**Scrip ID: 512217**

**Subject: Outcome of Board of Directors Meeting held on Monday, 04<sup>th</sup> December, 2017**

Dear Sir/Madam


Pursuant to the provisions of Regulations 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Monday, 04<sup>th</sup> December, 2017 at 2:00 p.m.:

1. Consider and Approved and taken on records the Un-Audited Financial Results along with Limited Review Report for the quarter and Half Year ended on September 30, 2017 as recommended by the Audit Committee.  
Further, we hereby enclose the following:
  - a. Un-Audited Financial Results for the quarter and Half Year ended on September 30, 2017.
  - b. Limited Review Report from the Statutory Auditor of the Company.
2. Approved the Appointment of Mr. Sehejbir Singh, Ms. Simmi Chhabra as Additional Director of the Company subject to approval of the Shareholders at the next General Meeting for a term of five years.
3. Approve the Appointment of Mr. Gursimran Singh, director of the company as Chief Financial Officer (CFO) of the Company

You are requested to take the same on record and acknowledge receipt.

Thanking You,

For, **PRISM MEDICO AND PHARMACY LIMITED**  
**For PRISM MEDICO AND PHARMACY LIMITED**

  
**Jasjot Singh** AUTHORISED SIGNATORY  
**Executive Director**  
**DIN: 01937631**



# Harjeet Parvesh & Company

## CHARTERED ACCOUNTANTS

### Limited Review Report

To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the accompanying statement of Un-audited Financial Result of **M/s. Prism Medico And Pharmacy Ltd** having its Regd. Office at 23/91, white Bunglow, Yashwant Nagar, Near Filmistan studio & Patkar College, opposite BMC School, Goregaon West, Mumbai – 400062 for the Quarter and Six months ended 30<sup>th</sup> September, 2017 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of company's Management and has been approved by the board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any martial misstatement.

Date: 29/11/2017  
Place: Mohali

For Harjeet Parvesh & Co.  
Chartered Accountants

Firm Regn. No. 017437N



CA Harjeet Singh  
Partner  
M.No 095466

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109MH2002PLC206595

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2017 (IN LAKHS)

PARTICULARS	Quarter Ended 30th Sept, 2017 UNAUDITED	Quarter Ended 30th June 2017 UNAUDITED	Quarter Ended 30th Sept, 2016 UNAUDITED	Half Year Ended 30th Sept, 2017	Year Ended 31st MARCH 2017 AUDITED
1 INCOME FROM OPERATIONS	516.71	514.79		1,031.50	-
Net Sales / Income from Operations (Net of Excise A) Duty)					
2 OTHER OPERATING INCOME					-
3 TOTAL INCOME FROM OPERATIONS (net)	516.71	514.79		1,031.50	-
4 EXPENSES:					
PURCHASE OF STOCK-IN-TRADE	496.43	411.58		908.01	-
CHANGE IN INVENTORIES	0.00	79.00		79.00	-
EMPLOYEE BENEFIT EXPENSES	0.95	0.30		1.25	-
FINANCE COSTS	0.00	0.00		0.00	-
PAYMENT TO BSE		-		-	9.14
DEPRECIATION	0.51	0.51		1.01	-
OTHER EXPENSES	6.13	4.14	0.55	10.27	1.45
TOTAL EXPENSES	504.02	495.53	0.55	999.55	10.59
5 PROFIT BEFORE TAX	12.69	19.26	(0.55)	31.94	(10.59)
6 TAX EXPENSE:					
(1)CURRENT TAX		-			-
(2)DEFERRED TAX					-
7 PROFIT/(LOSS) FOR THE PERIOD	12.69	19.26	(0.55)	31.94	(10.59)
8 OTHER COMPREHENSIVE INCOME, NET OF INCOME TAX		-			-
A) i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS		-			-
ii) INCOME TAX RELATING TO ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS		-			-
B) i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS		-			-
ii) INCOME TAX RELATING TO ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS		-			-
Total Other Comprehensive income, net of income tax		-			-
9 TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	12.69	19.26	-0.55	31.94	-10.59
PAID UP EQUITY SHARE CAPITAL: (FACE 10 VALUE RS. 10 EACH)	606.3428	606.3428	199.2	606.3428	199.2
11 EARNINGS PER EQUITY SHARE					
(1)BASIC	0.02	0.32	(0.03)	0.05	(0.53)
(2)DILUTED	0.02	0.32	(0.03)	0.05	(0.53)

### Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 4th December, 2017. The Financial results for the Quarter ended has been subjected to limited review by the company's auditor.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

For PRISM MEDICO AND PHARMACY LIMITED

770 + 1ph

AUTHORISED SIGNATORY



**PRISM MEDICO AND PHARMACY LTD.**

**CIN : L51109MH2002PLC206595**

4. The Ind AS compliant financial results, pertaining to period ended Sept 30, 2016 have not been subject to limited review or audit as the same is not mandatory as per SEBI's circular CIR/CFD/FAC/62/2016, dated July 5, 2016. on account of implementation of Ind-AS by listed companies.

5. The statement does not include Ind AS compliant results for the previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

This reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 5, 2016 on account of implementation of Ind-AS by listed companies.

**For and on behalf of Board of Prism medico and Pharmacy Limited**

**For PRISM MEDICO AND PHARMACY LIMITED**

70+1+6

**Jasjot Singh** **AUTHORISED SIGNATORY**

**Executive**

**Director**

**DIN: 01937631**

Place : Mumbai

Date :

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109MH2002PLC206595

## STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH QUARTER ENDED (IN LAKHS)

PARTICULARS	Quarter Ended 30th Sept, 2017	Quarter Ended 30th June 2017	Half Year Ended 30th Sept, 2017
1 REVENUE FROM OPERATIONS	561.46	1,210.48	1,771.94
2 OTHER INCOME	0.30	0.87	1.17
3 TOTAL REVENUE	561.76	1,211.35	1,773.11
4 EXPENSES:			
PURCHASE OF STOCK-IN-TRADE	496.43	847.37	1,343.80
CHANGE IN INVENTORIES	0.00	106.51	106.51
EMPLOYEE BENEFIT EXPENSES	3.85	4.70	8.55
FINANCE COSTS	6.48	7.74	14.22
COST OF MATERIAL CONSUMED	42.73	151.93	194.66
PAYMENT TO BSE		-	-
DEPRECIATION	11.60	8.23	19.83
OTHER EXPENSES	14.64	17.23	31.87
TOTAL EXPENSES	575.73	1,143.71	1,719.44
5 PROFIT BEFORE TAX	-13.97	67.64	53.67
6 TAX EXPENSE:			
(1) CURRENT TAX		-	-
(2) DEFERRED TAX		-	-
7 PROFIT (LOSS) FOR THE PERIOD	-13.97	67.64	53.67
8 OTHER COMPREHENSIVE INCOME, NET OF INCOME TAX		-	-
A) i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS		-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS		-	-
B) i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS		-	-
ii) INCOME TAX RELATING TO ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS		-	-
Total Other Comprehensive income, net of income tax		-	-
9 TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	-13.97	67.64	53.66891
PAID UP EQUITY SHARE CAPITAL:			
10 (FACE VALUE RS. 10 EACH)	606.3428	606.3428	606.3428
11 EARNINGS PER EQUITY SHARE			
(1) BASIC	-0.23	1.12	0.89
(2) DILUTED	-0.23	1.12	0.89

### Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 04th December, 2017.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

For PRISM MEDICO AND PHARMACY LIMITED

5770+14

AUTHORISED SIGNATORY

**PRISM MEDICO AND PHARMACY LTD.**

**CIN : L51109MH2002PLC206595**


---

4. The statement does not include Ind AS compliant results for the previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016.

This reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 5, 2016 on account of implementation of Ind-AS by listed companies.

**For and on behalf of Board of Prism medico**

**For PRISM MEDICO AND PHARMACY LIMITED**



**Jasjot Singh** AUTHORISED SIGNATORY  
**Executive Director**

**DIN: 01937631**

Place : Mumbai

Date :